04.21.26 -- What If The U.S. Government Stopped Funding Biotech?

Explore the partnership enabling Transcat to meet regulatory requirements while focusing on core R&D and accelerating the delivery of life-changing therapies.

Computational Fluid Dynamics simulation is essential for robust biologics tech transfer. See how this predictive tool optimizes critical scale-up processes, reducing risk and expediting time to market.

Antibody-drug conjugates' manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill & finish.

Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.

Regulators require clear, verifiable proof that production cell lines originate from a single progenitor cell, supported by strong imaging, documentation, and data integrity to ensure product consistency and safety.

Controlled nucleation standardizes freezing across all vials, leading to uniform ice crystals and improved lyo cake quality. This critical step reduces variability and supports robust product scale-up.

To ensure speed and stability in the manufacture of your complex biologic — mAbs, antibodies, fusion proteins, and/or antibody drug conjugates — prioritize a high-performance CLD workflow.

Learn about the University of Queensland's rapid development of a vaccine candidate for COVID-19 and the role GS Xceed® system played in this project.

Growing use of large‑volume subcutaneous therapies is increasing demand for wearable injectors that reduce user error, simplify preparation, and enhance safety through human‑factors‑focused design.

Accelerate from development to commercialization with scalable manufacturing solutions. Integrated digital systems and expert technical advocacy ensure regulatory excellence and rapid batch release.